Stalevo® is a combination of levodopa, carbidopa and entacapone. It was initially approved based on pharmacokinetic studies demonstrating bioequivalence with Sinemet® immediate release (IR ...
Stalevo induced more dyskinesia than similar dosages of levodopa/carbidopa, so the regimen tested (target maintenance dose Stalevo 100 four-times daily given q3.5 h) is not recommended in this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback